Table 2 Chi-squared analysis of cancer somatic, germline and pharmacogenomic test ordering behaviour in the past year
From: Factors influencing cancer genetic somatic mutation test ordering by cancer physician
No. (%) of physicians ordered zero tests | No. (%) of physicians ordered ≥ 5 tests/year | Mean | Median | Range | p-value* | |
|---|---|---|---|---|---|---|
Somatic mutation tests (n = 102) | 17 (16.7%) | 67 (65.7%) | 27.4 | 10 | 0–200 | |
Germline tests (n = 102) | 39 (38.2%) | 48 (48.1%) | 7.2 | 2 | 0–50 | 0.009** |
Cancer Pharmacogenomic tests (n = 100) | 75 (75%) | 11 (11%) | 1.04 | 0 | 0–20 | < 0.00001** |